中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
21期
87-88
,共2页
莉芙敏%绝经期%生殖道萎缩%疗效%安全性
莉芙敏%絕經期%生殖道萎縮%療效%安全性
리부민%절경기%생식도위축%료효%안전성
remifemin%menopause%genital atrophy%efficacy%safety
目的 探讨莉芙敏改善绝经期妇女生殖道萎缩症状的疗效.方法 选择绝经期生殖道萎缩患者112例,随机分为对照组和观察组,各56例.对照组患者采用戊酸雌二醇片治疗,观察组患者采用莉芙敏片治疗,疗程均为12周.结果 治疗后,两组患者萎缩症状评分较治疗前均有降低,两组间降低程度未见明显差异( P>0. 05);两组患者阴道健康评分均有提升( P<0. 05),且观察组提升较对照组更显著( P<0. 05 );两组患者体内血清雌二醇含量均有升高,但对照组升高更显著( P<0. 05);对照组子宫内膜厚度有所增厚( P<0. 05),观察组未见明显改变( P>0. 05).对照组患者不良反应发生率显著高于观察组患者( P<0. 05).结论 莉芙敏改善绝经期生殖道萎缩的疗效确切,且较传统激素替代治疗安全性更好.
目的 探討莉芙敏改善絕經期婦女生殖道萎縮癥狀的療效.方法 選擇絕經期生殖道萎縮患者112例,隨機分為對照組和觀察組,各56例.對照組患者採用戊痠雌二醇片治療,觀察組患者採用莉芙敏片治療,療程均為12週.結果 治療後,兩組患者萎縮癥狀評分較治療前均有降低,兩組間降低程度未見明顯差異( P>0. 05);兩組患者陰道健康評分均有提升( P<0. 05),且觀察組提升較對照組更顯著( P<0. 05 );兩組患者體內血清雌二醇含量均有升高,但對照組升高更顯著( P<0. 05);對照組子宮內膜厚度有所增厚( P<0. 05),觀察組未見明顯改變( P>0. 05).對照組患者不良反應髮生率顯著高于觀察組患者( P<0. 05).結論 莉芙敏改善絕經期生殖道萎縮的療效確切,且較傳統激素替代治療安全性更好.
목적 탐토리부민개선절경기부녀생식도위축증상적료효.방법 선택절경기생식도위축환자112례,수궤분위대조조화관찰조,각56례.대조조환자채용무산자이순편치료,관찰조환자채용리부민편치료,료정균위12주.결과 치료후,량조환자위축증상평분교치료전균유강저,량조간강저정도미견명현차이( P>0. 05);량조환자음도건강평분균유제승( P<0. 05),차관찰조제승교대조조경현저( P<0. 05 );량조환자체내혈청자이순함량균유승고,단대조조승고경현저( P<0. 05);대조조자궁내막후도유소증후( P<0. 05),관찰조미견명현개변( P>0. 05).대조조환자불량반응발생솔현저고우관찰조환자( P<0. 05).결론 리부민개선절경기생식도위축적료효학절,차교전통격소체대치료안전성경호.
Objective To detect the efficacy of remifemin on improving menopausal symptoms of genital atrophy. Methods 112 cases of patients with postmenopausal genital atrophy were randomly divided into control group and observation group, 56 cases in each group. The control group used Estradiol Valerate Tablets, the observation group were treated with Remifemin Tablets; the treatment for both groups lasted for 12 weeks. Results The atrophy symptom scores of the two groups were decreased compared with before treat-ment, and there was no significant difference between the two groups ( P > 0. 05 ) . The vaginal health scores of the two groups were im-proved ( P < 0. 05 ) , and the observation group improved more significantly ( P < 0. 05 ) . The serum estradiol content of the two groups were increased, but the control group increased more significantly ( P < 0. 05 ) . The endometrial thickness of the control group increased ( P < 0. 05 ) , and the observation group had no significant change ( P > 0. 05 ) . The occurrence rate of adverse reactions of the control group was significantly higher than those of the observation group ( P < 0. 05 ) . Conclusion Remifemin has clear effect on improving menopausal reproductive tract atrophy, and has good safety compared with the traditional hormone replacement therapy.
